Halozyme Therapeutics has announced plans to discontinue the development of its investigational cancer drug, PEGPH20, after it failed in the Phase III HALO-301 clinical trial involving metastatic pancreatic cancer patients.

The trial assessed the combination of PEGPH20 with gemcitabine and nab-paclitaxel (Abraxane).

It did not meet the primary endpoint, where the combination failed to show an improvement in median overall survival versus gemcitabine and nab-paclitaxel alone.

The company added that PEGPH20 demonstrated a higher response rate. However, no improvements were observed in overall survival, duration of response or progression-free survival.

Halozyme Therapeutics president and CEO Dr Helen Torley said: “Patients in both treatment arms of the HALO-301 trial surpassed the published median overall survival rates from the pivotal registration study of Abraxane plus gemcitabine as first-line therapy for metastatic pancreas cancer, published in 2013.

“Based on the lack of benefit over standard-of-care in this study, which performed well versus published data, we will be discontinuing PEGPH20 clinical development. This well-designed and well-executed study did not have the outcome that we or the study participants wanted or expected.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company plans to restructure to focus on its Enhanze drug delivery technology, including discontinuation of PEGPH20 development activities and closing its oncology operations.

As part of the restructuring, the company will cut nearly 55% or 160 jobs. Halozyme said that 80% of the reduction will be completed by January next year.

The remaining 120 employees will work to bolster Enhanze technology, primarily in areas required to support partners such as product development, manufacturing, quality and regulatory.

In addition, 12 employees will promote Halozyme’s commercial drug Hylenex.

Restructuring and additional cost-saving efforts are expected to save $130m to $140m for the company next year.